Pulike Biological Engineering (603566) - Total Liabilities
Based on the latest financial reports, Pulike Biological Engineering (603566) has total liabilities worth CN¥513.09 Million CNY (≈ $75.08 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pulike Biological Engineering - Total Liabilities Trend (2009–2024)
This chart illustrates how Pulike Biological Engineering's total liabilities have evolved over time, based on quarterly financial data. See 603566 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Pulike Biological Engineering Competitors by Total Liabilities
The table below lists competitors of Pulike Biological Engineering ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Indonesian Paradise Property
JK:INPP
|
Indonesia | Rp3.47 Trillion |
|
Kaufman Et Broad
PA:KOF
|
France | €1.21 Billion |
|
Yinchuan Xinhua Commercial Group Co Ltd
SHG:600785
|
China | CN¥6.47 Billion |
|
Kunwu Jiuding Investment Holdings Co Ltd
SHG:600053
|
China | CN¥227.87 Million |
|
GREENLIGHT CAP.RE A DL-01
F:G8L
|
Germany | €1.53 Billion |
|
ST Barbara Ltd
AU:SBM
|
Australia | AU$197.04 Million |
|
Andersen Group Inc.
NYSE:ANDG
|
USA | $579.88 Million |
|
Anhui Jinchun Nonwoven Co Ltd
SHE:300877
|
China | CN¥274.86 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Pulike Biological Engineering's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pulike Biological Engineering market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pulike Biological Engineering's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pulike Biological Engineering (2009–2024)
The table below shows the annual total liabilities of Pulike Biological Engineering from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥471.11 Million ≈ $68.94 Million |
-12.49% |
| 2023-12-31 | CN¥538.33 Million ≈ $78.78 Million |
-8.46% |
| 2022-12-31 | CN¥588.07 Million ≈ $86.05 Million |
+59.88% |
| 2021-12-31 | CN¥367.83 Million ≈ $53.82 Million |
+15.25% |
| 2020-12-31 | CN¥319.16 Million ≈ $46.70 Million |
+29.00% |
| 2019-12-31 | CN¥247.42 Million ≈ $36.21 Million |
-7.51% |
| 2018-12-31 | CN¥267.51 Million ≈ $39.15 Million |
+13.22% |
| 2017-12-31 | CN¥236.27 Million ≈ $34.57 Million |
-7.67% |
| 2016-12-31 | CN¥255.91 Million ≈ $37.45 Million |
+53.71% |
| 2015-12-31 | CN¥166.49 Million ≈ $24.36 Million |
+8.01% |
| 2014-12-31 | CN¥154.14 Million ≈ $22.56 Million |
+21.04% |
| 2013-12-31 | CN¥127.35 Million ≈ $18.64 Million |
-10.10% |
| 2012-12-31 | CN¥141.66 Million ≈ $20.73 Million |
-25.17% |
| 2011-12-31 | CN¥189.31 Million ≈ $27.70 Million |
-22.94% |
| 2010-12-31 | CN¥245.65 Million ≈ $35.95 Million |
+218.22% |
| 2009-12-31 | CN¥77.19 Million ≈ $11.30 Million |
-- |
About Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.